|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Commercialization of "Humanized" monoclonal antibody to treat AIDS and other diseases. |
|
| Management |
| David Horowitz, Investor Relations |
| |
|
|
| |
|
| Keywords |
| aids, humanized monoclonal antibodies, HIVAIDS |
|
|
|
| Description |
|
SRD-Pharma is a engaged in the development and commercialization of "Humanized" monoclonal antibody based drugs for the treatment of various diseases including AIDS. |
|
| Products / Services |
The company currently has a portfolio of 4 U.S. patents, 16 corresponding foreign patents and 4 additional patents pending for various "humanized" monoclonal antibodies for the therapeutic treatment of HIV.
|
|
| Technology / Differentiation |
| "Humanized" monoclonal antibody based drugs are expected to become relevant in the treatment of autoimmune and inflammatory disorders, cardiovascular diseases, organ transplants, and infectious diseases. Amongst the principal benefits of monoclonal antibodies is their ability to target specific cells or chemical mediators that could be involved in disease causation. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members